JPY 1091.0
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -258.21 Million JPY | 28.84% |
2022 | -362.89 Million JPY | -117.8% |
2021 | -166.61 Million JPY | 3.24% |
2020 | -172.19 Million JPY | -38.87% |
2019 | -124 Million JPY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -19 Million JPY | 15.87% |
2023 Q2 | -64.74 Million JPY | 32.23% |
2023 Q4 | -22.58 Million JPY | 70.03% |
2023 Q3 | -75.36 Million JPY | -16.4% |
2023 FY | -258.21 Million JPY | 28.84% |
2023 Q1 | -95.52 Million JPY | -134.26% |
2022 Q3 | -116 Million JPY | -18.66% |
2022 FY | -362.89 Million JPY | -117.8% |
2022 Q4 | -40.77 Million JPY | 64.85% |
2022 Q2 | -97.75 Million JPY | 0.0% |
2021 FY | -166.61 Million JPY | 3.24% |
2020 FY | -172.19 Million JPY | -38.87% |
2019 FY | -124 Million JPY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Shin Nippon Biomedical Laboratories, Ltd. | 4.16 Billion JPY | 106.204% |
Cosmo Bio Company,Limited | 519 Million JPY | 149.753% |
H.U. Group Holdings, Inc. | -4.04 Billion JPY | 93.613% |
FALCO HOLDINGS Co., Ltd. | 2.15 Billion JPY | 111.999% |
BML, Inc. | 9.16 Billion JPY | 102.816% |
Human Metabolome Technologies, Inc. | 220.16 Million JPY | 217.281% |
Precision System Science Co., Ltd. | -956.24 Million JPY | 72.997% |